If you haven’t visited Louisville, Ky., lately, you might not recognize it. The entire downtown is nearing the completion of a $1 billion revitalization. On virtually every corner there’s something new popping up—new Bourbon distilleries, new Southern-inspired culinary destinations and new places to explore.
Overcoming the low success rate of new CNS Therapeutics
12th April 2011 - Central London, UK
Event contact title
Event contact first name
Event contact last name
Event contact telephone number
+44 (0)20 7827 6186
The CNS therapeutic area covers wide range of diseases, including psychiatric and neurological diseases and also symptom classes which span a number of diseases, like pain and spasticity. The diseases share the common property that primary mechanisms leading to expression of the disease are in the brain and spinal cord. Despite the high prevalence of many of these diseases, they are still poorly treated. Attrition rates for new drug development are higher than any other therapeutic area, and have led to several companies withdrawing resource from the area. Indeed there are issues at every stage of the discovery/development pathway including: an inadequate understanding of the aetiology and pathology, poorly predictive animal models, difficulties with drugs accessing the target organ, subjective clinical endpoints and, in some instances, uncertainty regarding outcomes that regulators will value. However, the commercial prizes are potentially great and the medical needs high, so the industry cannot disengage from the area altogether.